Medicaid, Medicare expand lung cancer screening, remove cost barriers

What it does

This bill requires Medicaid to cover annual lung cancer screening with no patient cost-sharing for people meeting U.S. Preventive Services Task Force guidelines, expands Medicaid coverage of tobacco-cessation counseling and drugs to all Medicaid enrollees (not just pregnant women), and extends the same no-prior-authorization lung cancer screening requirement to Medicare and private health insurance. It also funds a $10 million/year education campaign (2026–2030) and directs a study of lung cancer screening gaps in underrepresented populations.

Why we flagged it

The bill's core mechanism is a mandate to cover evidence-based preventive screening and cessation services across public and private insurance with no cost-sharing or administrative barriers. It is a straightforward public-health measure aligned with clinical guidelines.

What the text implies

• Expansion of tobacco-cessation coverage to all Medicaid enrollees (not just pregnant women) may increase demand for cessation services; states will bear the cost unless federal matching funds increase.
• Prior authorization removal across Medicare, Medicaid, and private plans may increase screening volume; cost impact depends on uptake and whether screening reduces downstream cancer treatment costs.
• Education campaign ($10M/year) targets high-risk populations; effectiveness depends on implementation and reach, but may identify screening gaps in firefighters, veterans, and younger women not currently captured in guidelines.
• Study requirement (Comptroller General report) may lead to future guideline changes or coverage expansions if underrepresented populations are identified as having unmet screening needs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicaid and Medicare beneficiaries gain access to evidence-based lung cancer screening and tobacco-cessation support without cost-sharing or prior authorization delays. The expansion of tobacco-cessation coverage to all Medicaid enrollees (not just pregnant women) removes a prior restriction. Private insurance enrollees also benefit from the no-prior-authorization requirement. The bill funds public education to reach high-risk populations.

Who stands to gain

• Diagnostic imaging providers (CT scan facilities)
• Pulmonology and primary care practices
• Pharmaceutical companies (tobacco-cessation drugs)
• Behavioral health providers (counseling services)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), U.S. Preventive Services Task Force (USPSTF), Department of Health and Human Services (HHS), Medicaid State plans, Medicare (Parts A, B, and Advantage), Private health insurers, Comptroller General of the United States

Where it stands

7 cosponsors: 5 Democrats, 2 Republicans.

• Nov 20, 2025 — Introduced · Congress.gov: “Introduced in House”
• Nov 20, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,810,000 in lobbying spend. A filing names 40 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Kathy Castor, the sponsor, reported $1,028,281 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• American Lung Association — $190,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.